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≥+2; P = 0.002,) and pHER2 (0 vs. ≥+1; P = 0.001) expressions were 
signiﬁcantly associated with incidence of EGFR mutation.
Conclusions: EGFR mutation was a signiﬁcant predictive biomarker 
of response to geﬁtinib. Phosphorylated EGFR protein expression is a 
potent replaceable biomarker for EGFR mutation.
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Background: EGFR mutations have been recognized as a predictor of 
favorable clinical outcomes in non-small-cell lung cancer (NSCLC) pa-
tients treated with geﬁtinib. Never-smoking status is also considered to 
be a predictive factor and may be a determinant for geﬁtinib treatment. 
We have independently reported the relationship between EGFR muta-
tions and clinical beneﬁt in NSCLC patients treated with geﬁtinib. In 
this study, we combined our data and re-analyzed the factors that would 
affect on clinical outcome in patients treated geﬁtinib. 
Methods: The EGFR mutation status restricted in exon19 deletion and 
L858R exon21 mutation was determined in 408 NSCLC patients who 
were treated with geﬁtinib using PCR-based assay. The clinical record 
including clinicopathological factors, tumor response and survival time 
were reviewed for 408 patients and correlated with EGFR status. 
Results: In the total case, tumor response was observed in 155 patients 
showed tumor response and 239 patients showed no response. Fourteen 
patients were not evaluable. Among examined factors, EGFR mutation 
was only signiﬁcant factor for tumor responsiveness (p<0.0001), pro-
longed overall (p<0.0001) and progression-free survivals (p<0.0001) 
by multivariate analysis. To analyze the impact of EGFR mutation 
and smoking on treatment outcomes with geﬁtinib, we classiﬁed our 
patients into 4 groups based on EGFR mutation and smoking status: 
(A) 104 patients with EGFR mutation and never-smoking history, (B) 
64 patients with EGFR mutation and smoking history, (C) 74 patients 
with EGFR wild-type and never smoking history, (D) 166 patients 
with EGFR wild-type and smoking history. The survival times includ-
ing overall survival and progression-free survival of each group were 
compared (Fig.1). There was no signiﬁcant difference among A and 
B groups or among C and D groups. There was signiﬁcant difference 
between A or B and C or D groups, conﬁrming that the EGFR mutation 
not smoking status is a predictor for a prolonged survival of patients 
(A vs C, p<0.0001; A vs D, p<0.0001, B vs C, p=0.0004); B vs D, 
p<0.0001). 
Conclusions: Our large-scale data indicates that EGFR mutation at 
exons 19 and 21 status is a predictive factor for favorable clinical out-
come in patients treated with geﬁtinib. 
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OX-40, also known as CD134, is a 50-kDa type-I membrane glycopro-
tein that belongs to the tumor necrosis factor (TNF) receptor superfam-
ily and serves as a T-cell co-stimulatory molecule. In vivo, deliberate 
ligation of OX40 in tumor-bearing mice induced tumor eradication, 
whereas, in some of the models, administration of agonistic OX40 
monoclonal antibody (mAb) alone was not sufﬁcient to induce tumor 
eradication. Our preliminary experiments also showed insufﬁcient 
therapeutic outcome using agonistic anti-OX40 mAb alone. Therefore, 
development of more powerful strategies is deﬁnitely required to aug-
ment immunotherapeutic effects with agonistic anti-OX40 mAb. Ioniz-
ing radiotherapy is one of the core modalities for treatment of localized 
cancer. However, radiation can cause additional immunosuppressive 
effects in the cancer host through bone marrow suppression, resulting 
in reduction of the absolute number of cells responsible for immunity 
and elevated levels of irradiated tissue-derived TGF-β and IL-10. In 
contrast, it has been shown that irradiation has a role in enhancing 
tumor immunogenicity and homing effector cells to the tumor site via 
induction of tumor apoptosis and upregulation of MHC, costimulatory, 
and adhesive molecules on tumor cells. Under these circumstances, in-
vestigators have attempted to optimize the use of irradiation in concert 
with various immunological modalities such as recombinant cytokines, 
cytokine-gene-transduced tumor or virus vaccinations, dendritic cells, 
agonistic anti-CD40 monoclonal antibody, ex vivo activated cells from 
draining lymph nodes (DLNs), adoptive transfer of antigen-speciﬁc T 
cells and peritumoral injection of CpG ologodeoxynucleotide in mouse 
experimental models. Based on the previous knowledge, we focused on 
irradiation as an immunological partner of agonistic anti-OX40 mAb 
therapy. In the present study, we attempted to elucidate the therapeutic 
effect of combining agonistic anti-OX40 mAb and irradiation in a mu-
rine lung cancer model. After intradermal transplantation of ovalbumin-
transfected LLC (LLC-OVA), C57BL/6 mice were locally irradiated 
with a single dose of 20Gy in combination with intratumoral injec-
tion of anti-OX40 mAb at 50μg on day 4 when the inoculated tumor 
reached a diameter of 7 to 9 mm. On day 8, 11 and 14, the tumor-bear-
ing mice were further treated with the same dose of anti-OX40 mAb. 
Anti-OX40 mAb in combination with radiotherapy provided greater ef-
ﬁcacy than either single treatment against well-established tumors and 
prolonged survival. In vivo depletion study suggested that therapeutic 
immunity was mainly CD8+ T cell-dependent. OX40+CD8+ T cells were 
augmented in draining lymph nodes (DLNs) obtained from irradi-
ated mice compared with those from non-irradiated mice. OVA-MHC 
tetramer+ CD8+ T cells were highly recruited in DLNs obtained from 
mice treated with anti-OX40 mAb in combination with radiotherapy, 
